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ABSTRACT
Sickle cell trait (SCT), sickle cell disease’s carrier status, is a common genetic
variant found in many people of African, South Asian, Middle Eastern and Mediterranean
descent. While overall considered a benign carrier status, it has been associated with an
increased risk of several diseases, including exertional rhabdomyolysis (ER), and chronic
kidney disease. While epidemiological evidence links SCT with ER, the actual
pathophysiological mechanism less understood. Additionally, while there is an increased
prevalence of atrial fibrillation (AF) documented in people with sickle cell disease,
studies in individuals with SCT are lacking.
The objectives of this thesis are twofold: The first chapter is a literature review
of studies to examine the physiological mechanisms linking SCT and exertional
rhabdomyolysis. The second chapter is original research into the associations of SCT
with AF.
The first chapter reviews studies that identify aggravating factors that may
promote ER. It then reviews observed pathophysiological changes in people with SCT
that may increase the risk of ER. It summarizes studies that assess mitigating factors that
decrease the risk of ER. It then presents a postulated pathway of mechanisms that
associate SCT with ER.
The second chapter uses data from African-American participants in the REasons
for Geographic and Racial Differences in Stroke (REGARDS) study to assess the
association of SCT with prevalent AF (by electrocardiogram or medical history) using
logistic regression models adjusting for age, sex, income, education, history of stroke,
myocardial infarction, diabetes, hypertension, and chronic kidney disease. In 10,409
participants with baseline ECG data and genotyping, 778 (7.5%) had SCT and 811
(7.8%) had prevalent AF. After adjusting for age, sex, education and income, SCT was
associated with AF, OR 1.32 (95% CI 1.03-1.70). SCT remained associated with
prevalent AF after adjusting for potential factors on the causal pathway such as
hypertension and chronic kidney disease suggesting alternate mechanisms for the
increased risk. SCT was associated with a higher prevalence of AF and a nonsignificantly higher incident AF over a 9.2 year period independent of AF risk factors.
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CHAPTER 1: SICKLE CELL TRAIT AND EXERTIONAL
RHABDOMYOLYSIS: A REVIEW OF THE KNOWN
PATHOPHYSIOLOGICAL MECHANISMS
1.1. Introduction
Sickle Cell Trait (SCT) is the carrier condition in which individuals carry one
abnormal allele of the hemoglobin beta-chain gene (encoding β-globin), hemoglobin S
(HbS). SCT has a prevalence of 7.3 % among African Americans, 0.7% of Latinos, and
0.3% of Caucasians in the United States and 10-40% across equatorial Africa (Ojodu et
al., 2014). As individuals with SCT carry one allele for one normal β-globin and one
sickle hemoglobin, it is also termed hemoglobin AS (Hb AS). Sickle Cell Disease (SCD)
occurs when an individual inherits two abnormal β-globin genes. Traditionally, SCT has
been considered a benign condition and is known to be associated with a decreased risk
of developing complications from falciparum malaria (Williams et al., 2005), and is
prevalent in the same geographic distribution as falciparum malaria. There is however
moderate to strong epidemiological evidence that now links SCT to an increased risk of
developing chronic kidney disease, venous thromboembolism, and exertional
rhabdomyolysis (R. P. Naik et al., 2018).
The purpose of this review is to evaluate the current understanding of the
pathophysiological mechanisms linking SCT and exertional rhabdomyolysis as well as
the real and perceived implications for individuals with SCT. Individuals with SCT have
historically been, and can currently be, excluded from sports and military service.
Exertional rhabdomyolysis is on the postulated causal pathway between SCT and sudden
1

death, with a reported relative risk of sudden death of 28 in military recruits (Kark,
Posey, Schumacher, & Ruehle, 1987) and 37 in NCAA athletes (Harmon, Drezner,
Klossner, & Asif, 2012) for SCT individuals . However, recent epidemiological research
with military personnel has documented a lower risk of exertional rhabdomyolysis with
SCT (hazard ratio [HR], 1.54; 95% confidence interval [CI], 1.12 to 2.12), and finding no
firm association between SCT and sudden death (HR, 0.99; 95% CI, 0.46 to 2.13)
(Nelson et al., 2016). It is unclear if these discordant clinical observations are due to
methodologic limitations or from the implementation of better preventative measures
over time. An understanding of the mechanistic causes of SCT-associated
rhabdomyolysis will help to make changes to decrease the risk of adverse events and
better inform policy decisions like universal screening of SCT in NCAA athletes and
service members.
The first association with SCT and its protective effects from complications of
plasmodium falciparum Malaria was noted in the late 1940s when there were significant
differences in the levels of parasitemia noted in individuals with and without SCT
(Allison, 1954; Beet, 1946).
Multiple case reports and small case series were published documenting adverse
clinical outcomes in SCT carriers, including splenic infarcts, hematuria and bacteriuria
beginning in the 1960s and 1970s (Sears, 1978). It was noted at the time that there was no
evidence for decreased overall survival and that properly controlled studies were lacking.
Nevertheless, this led to SCT screening and exclusion from some forms of service in the
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US military due to concerns about sudden death and developing complications at high
altitude (Brodine & Uddin, 1977). These concerns were later rescinded.
Clinical research in the past 10 years has progressed as more rigorous, prospective
cohort studies have been published. A recent systematic review noted that there are
multiple studies published with a high level of evidence that there is an association with
SCT and developing venous thromboemboli, proteinuria, chronic kidney disease, but
only a moderate level strength of evidence associating exertional rhabdomyolysis with
SCT and a low strength of evidence with sudden death (R. P. Naik et al., 2018).
Rhabdomyolysis is a life-threatening syndrome resulting from skeletal muscle
breakdown and release of cellular contents into the circulatory system. This includes
creatine kinase, myoglobin, and electrolytes including potassium (Visweswaran &
Guntupalli, 1999). While there are multiple known causes of rhabdomyolysis, the final
pathway leading to muscle breakdown and release of intracellular contents is the same.
Muscles are reliant on adenosine triphosphate (ATP) to maintain low intracellular sodium
and potassium levels. If ATP is depleted, these intracellular gradients cannot be
maintained. High amounts of intracellular sodium and potassium in the cell lead to
increased activity of proteolytic enzymes which release intracellular contents (Khan,
2009). Excessive muscle activity is thought to trigger rhabdomyolysis by depleting ATP
so production cannot keep up with demand (Sharma, Winpenny, & Heymann, 1999).
Trauma and burns which cause direct muscle injury, muscle ischemia, drugs and toxins,
and genetic disorders affecting glycogen metabolism such as McArdle’s disease, are also
associated with rhabdomyolysis (Khan, 2009).
3

HbS is a variant on the β-globin gene that results from a substitution of valine for
glutamic acid at the sixth amino acid position causing a missense mutation (AshleyKoch, Yang, & Olney, 2000). HbS polymerizes when hemoglobin is in the deoxygenated
state (Eaton & Hofrichter, 1990). Polymerization of HbS leads to decreased red blood
cell flexibility, increased adhesion of red cells to vascular endothelium, as well as
increased inflammation, coagulation and nitric oxide scavenging (Eaton & Bunn, 2017).
The lifespan of RBCs containing HbS is shorter than RBCs without HbS, but varies
significantly depending on the concentration of fetal hemoglobin (HbF) present (Franco
et al., 1998). The extent to which HbS polymerizes correlates to the clinical and
hemolytic severity in people with SCD (Brittenham, Schechter, & Noguchi, 1985).
1.1.1. Determinants of HBS percentage in SCT carriers.
Individuals with SCT typically have 35-40% HBS on hemoglobin electrophoresis
(Angastiniotis et al., 2013). While there are equal numbers of genes present to produce
equal amounts of HbA and HbS, HbS accounts for less than half of the total amount of
hemoglobin present in carriers because HbS chains are less negatively charged and do not
bind as readily to the α-subunit of hemoglobin (Forget & Bunn, 2013). The HbS
percentage is further reduced when people with SCT also carry a 1 or 2 α-globin gene
deletion (α -thalassemia silent carriers or α-thalassemia trait), conditions found in up to
30% of African-Americans (Steinberg & Embury, 1986). One study (Steinberg &
Embury, 1986) showed progressive decreases in hemoglobin S percentage as the number
of α-globulin gene deletions increased; those with 0, 1, or two α-globulin gene deletions
had HbS percentages of 35-45%, 30-35% and 25-30% respectively.
4

1.2. Postulated causal pathway linking SCT and ER
The mechanism by which exertional rhabdomyolysis in SCT carriers occurs is not
clear but is thought to be due to a combination of factors that increase the risk of muscle
microvascular occlusions and muscle ischemia. Factors associated with exertion that
increase this risk include metabolic acidosis, local hypoxemia around the capillaries of
exercising muscles as well as high intensity exercise. A combination of these factors in
turn causes increased viscosity of blood, release of inflammatory and vascular adhesion
molecules, vascular remodeling and oxidative stress. These physiological changes are in
turn thought to cause microvascular occlusions that lead to muscle ischemia, triggering
ATP depletion, and rhabdomyolysis. Mitigating factors include degree of physical

Figure 1: Postulated mechanism of sickle trait and rhabdomyolysis
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fitness, the presence of alpha thalassemia trait, and adequate hydration. These
mechanisms are shown in figure 1.
It is not clear if cells need to be in a sickled state per se in order to cause
endothelial damage and capillary occlusion (Eichner, 2010) or if damage from RBC
sickling is only one of several mechanisms that lead to microvascular occlusions and
ischemia (Tripette et al., 2013). When blood from SCT carriers collected at rest was
exposed to acidic and deoxygenated in vitro environments to a similar degree to that seen
in strenuous exercise, a significantly increased RBC rigidity was detected that further
increased in an acidic environment relative to control blood even though no sickling was
observed (Xu et al., 2016).
1.2.1. Aggravating factors
1.2.1.1. Hypoxemia
A study of otherwise healthy SCT carriers and controls underwent arterial and
venous blood sampling before and after performing maximal arm crank exercises, once at
an altitude of 1,270 meters (PiO2 =127 mmHg), and again at a simulated level of 4000
meters (PiO2=85 mmHg). Even though there was a wide range of sickling, a significant
increase was found in the percentage of sickled cells in venous blood drawn from the arm
performing exercise. There was no association between exercise performance and degree
of sickling, and no significant difference in pH recorded at or after peak exercise between
the different simulated altitudes., There was, however, a significant increase in sickling
in blood from an exercising limb at 1,270 m and even more sickling in the limb at the
6

simulated 4000 m elevation, suggesting that differences in PiO2 rather than pH
contributed to sickling (Martin, Weisman, Zeballos, & Stephenson, 1989).
1.2.1.2. Acidosis
In contrast, there is also evidence that metabolic acidosis independently
contributes to increased RBC rigidity. An in vitro study (Xu et al., 2016) used a
microfluidic system that was capable of controlling oxygen and pH levels separately to
study RBC rigidity. They measured the degree of RBC stiffness by measuring the
change in RBC shape during and after shear stress was applied. They found that at
baseline, RBCs from healthy SCT volunteers were stiffer than those from controls, but
the stiffness increased further when RBC samples were measured under acidic
environments meant to match the local pH level of strenuous exercise. Of note, the
degree of rigidity in this study did not change under deoxygenated states; even in the
acidic environment, decreasing the local oxygen level did not change the level of
stiffness.
1.2.1.3. Intensive exercise
Intensive exercise can increase the blood viscosity in both healthy individuals and
SCT carriers. A study (Philippe Connes et al., 2006) measured blood viscosity, RBC
rigidity and hematocrit in both healthy subjects and SCT carriers during intense
exercising using a cycle ergometer conducted to maximal oxygen uptake (100% VO2
max) and 110% VO2 max. They found that SCT carriers had both elevated levels of
blood viscosity and RBC rigidity at baseline. Viscosity increased in both groups with
7

maximal and supramaximal exercise, and the increase in viscosity was maintained in
SCT carriers and continually stayed higher with exercise relative to controls. There was
no difference in plasma viscosity (as opposed to total blood viscosity) between the two
groups. RBC rigidity did not change with or without exercise.
1.2.2. Observed pathologic changes
1.2.2.1. Increased blood viscosity
Blood viscosity in SCT carriers increases with exercise. A study (Diaw et al.,
2014) involving 11 otherwise healthy male SCT carriers and 11 controls showed that
while blood viscosity in SCT carriers was higher at baseline relative to controls, during
vigorous exercise with and without access to water, the SCT carriers’ blood viscosity
decreased below resting values to the same level as controls, whereas when exercising
without water, blood viscosity rose over baseline.
1.2.2.2. Oxidative stress.
Reduced nitric oxide (NO) availability and dysregulated NO homeostasis is
known to play a role in the development of SCD complications (Kato, Gladwin, &
Steinberg, 2007). In SCD, hemolyzed RBCs release intravascular hemoglobin which
consumes NO, decreasing the availability of NO in the endothelium which in turn can
reduce vascular relaxation, increase platelet activation and expression of cell adhesion
molecules. While SCT carriers do not experience hemolysis to the extent that people
with SCD have, autoxidation also occurs with HbS molecules of SCT carriers which can
also contribute to oxidative stress (Barodka et al., 2014).
8

Though exercise in SCT is not associated with hemolysis, one study (Fasmall io et
al., 2012) noted that there were increased markers of oxidative stress in subjects with
SCT relative to normal controls. Interestingly, in subjects with both SCT and alpha
thalassemia, these effects were mitigated, with no significant changes in markers of
oxidative stress compared to people without SCT with or without α-thalassemia.
Another method to measure oxidative stress is to measure concentrations of the
heme degradation products oxyhemoglobin and methemoglobin (Nagababu, Fabry,
Nagel, & Rifkind, 2008). One study (Barodka et al., 2014) evaluated levels of heme
degradation products and levels of RBC deformability among four groups of children and
young adults: those with SCT, those with SCD who were not currently suffering a sickle
cell crisis, those currently in crisis, and healthy controls. The groups with SCT and SCD
all had significantly higher levels of heme degradation products and significantly lower
levels of deformability compared to healthy controls, with the patients in sickle cell crisis
being the most markedly abnormal, followed by the other patients with SCD currently in
a steady state, followed by the group with SCT. α-thalassemia status was not evaluated.
In contrast, a separate study (Tripette, Connes, et al., 2010) measuring adhesion
molecules, oxidative stress and nitric oxide markers after exercise in sickle cell trait
carriers with age-matched controls (and excluding people with α -thalassemia) did not
show any differences in markers of oxidative stress.
1.2.2.3. Increased RBC adhesion and release of inflammatory molecules.

9

Cellular adhesion interactions are known to be augmented with epinephrine
release in people with SCD (Hines et al., 2003). A study by Maciaszek et al(Maciaszek,
Andemariam, Huber, & Lykotrafitis, 2012) found that epinephrine increases the
frequency and strength of adhesion events between adhesion molecules on RBCs of SCT
carriers via BCAM/Lu and Intercellular adhesion molecule 4 (ICAM-4). BCAM/Lu,
also known as Lutheran group and basal cell adhesion molecule, antigens are present on
RBCs and adhere to the endothelial basement membrane (El Nemer et al., 2007). ICAM4 is also found on RBCs and had an increased frequency and strength of adhesion in SCT
RBCs relative to wild-type controls.

Of note, in the study, areas of increased adhesion

were able to be spatially mapped on the surface of RBCs, and adhesion molecules were
noted to be more heterozygously distributed on the hemoglobin of SCT carriers relative
to normal controls. This led the authors to speculate that HbS may disrupt the structure of
the RBC membrane resulting in aggregation when exposed to epinephrine.
There are significantly higher levels of vascular adhesion molecules in SCT
carriers with low amounts of physical activity compared to physically active SCT carriers
as well as controls when undergoing strenuous exercise. Aufradet et al (Aufradet et al.,
2010) performed a study measuring levels of soluble vascular cell adhesion molecule-1
(sVCAM), P-selectin and other markers of inflammation in a group of 32 subjects, half of
whom were SCT carriers. Half of the SCT carriers exercised regularly and half had
sedentary lifestyles. They performed measurements of these markers before and after
exercising, and found that while other inflammatory markers were not significantly
different between groups, the sedentary SCT carrier group had significantly higher levels
10

of sVCAM relative to the other three groups: active SCT carriers, active controls and
sedentary controls, none of whom differed significantly from each other.
A similar study evaluated levels of adhesion molecules in athletes with SCT with
α-thalassemia trait, athletes with SCT but no without α-thalassemia trait, and athletes
with neither SCT or α-thalassemia. Athletes who had SCT but no α-thalassemia had
higher levels of sVCAM-1 at baseline. All three groups had significant increases in
sVCAM-1 with exercise, but the elevated levels persisted longer during recovery in
people with SCT and no α-thalassemia. Participants with both SCT and α-thalassemia
had similar levels to the control group (Monchanin et al., 2008).
1.2.2.4. Vascular remodeling.
SCT carriers have a different skeletal muscle capillary structure compared to fitnessmatched controls. In a study by Vincent et al of 30 Cameroonian volunteers, 10 of whom
had normal hemoglobin, 5 with alpha thalassemia, 6 with SCT carrier status and 9 with
both SCT and α-thalassemia, significant differences were noted between groups (L.
Vincent et al., 2010). SCT carriers had a lower capillary density, and lower capillary
tortuosity. SCT carriers also had a significantly increased number of wider capillaries.
Participants with both SCT and α thalassemia trait had a significantly higher capillary
tortuosity relative to SCT carriers without α thalassemia. The study also measured
various endothelial markers and noted no differences in levels of soluble ICAM-1
(sICAM-1), sVCAM-1, sE-selectin, sP-selectin, IL-8, or IL-10 between SCT carriers and
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controls. A limitation of this study was that the participants were sedentary and blood
samples were not collected during exercise.
In a separate study by the same group, the researchers found that capillary density
increased with exercise in SCT carriers, however the differences between SCT carriers
and controls remained despite this increase (Lucile Vincent et al., 2012).
1.2.2.5. Microvascular occlusions.
Increased RBC rigidity, increased viscosity, RBC adhesion, inflammation and
vascular remodeling are all pathologic changes thought to contribute to microvascular
occlusions. There is also evidence that there are higher levels of coagulation activation
and inflammation markers in individuals with SCT. A study of individuals from Saudi
Arabia showed significantly elevated levels of D-dimer and lower levels of protein C,
protein S, and fibrinogen in individuals with SCT relative to normal controls (Adam et
al., 2008). D-dimer levels were also elevated in African American SCT carriers in the
Jackson Health Study relative to African American participants without SCT, with a
median D-dimer concentration of 0.55 μg/mL compared to 0.38 μg/mL (Rakhi P. Naik et
al., 2016).
However, actually observing microvascular occlusions in SCT carriers has been
only rarely reported, and even then, only in organs other than muscles. Anzalone et al.
reported the autopsy results of a 19 year old male SCT carrier who died after collapsing
during college football training who had focal packing of sickled red blood cells in the
spleen (Anzalone et al., 2010). Wirthwein et al. reported autopsies of three young SCT
12

carriers who died following physical exertion, and they noted occlusions in the
microvasculature of the heart, kidneys, and spleen (Wirthwein, Spotswood, Barnard, &
Prahlow, 2001).
In contrast, in studies of SCD, microvascular occlusions have been observed in
multiple settings: in autopsy specimens (Niraimathi, Kar, Jacob, & Basu, 2016), biopsy
specimens of SCD patients of both the microvasculature (Lipowsky, Sheikh, & Katz,
1987), and larger vessels (Stockman, Nigro, Mishkin, & Oski, 1972), and in mouse
models (Kaul, Fabry, & Nagel, 1989; Kaul, Finnegan, & Barabino, 2009; Manwani &
Frenette, 2013).
There is a well-documented association of venous thromboembolism risk with
SCT (Austin et al., 2007). However, it is not clear if the mechanisms and risk factors that
would trigger a venous thromboembolism would also cause microvascular occlusions.
1.2.3. Mitigating factors
1.2.3.1. Physical fitness
Markers of oxidative stress associated with exercise was decreased in SCT
carriers that exercise regularly relative to inactive SCT carriers. A study by Chirico et al.
(Chirico et al., 2012) studied levels of malondialdehyde (MDA, a byproduct of lipid
peroxidation and a marker of oxidative stress), antioxidant enzymes (superoxide
dysmutase, gludathione peroxidase, and catalase) as well as markers of nitric oxide
metabolism among SCT carriers that were sedentary, SCT carriers that played sports at
least 8 hours a week, and normal controls who exercised regularly or were sedentary.
13

The study observed that anti-oxidants and products of nitric oxide metabolism were
significantly increased in active SCT carriers. The greatest magnitude of difference was
from changes in plasma MDA. There was a significant increase in MDA in the sedentary
SCT participants during and after exercise, whereas none of the other subgroups
experienced any significant changes from baseline
1.2.3.2. Adequate hydration
Adequate hydration is important in mitigating the effects of heavy exercise at
least in part by decreasing blood viscosity. A study by Tripette et al (Tripette, Loko, et
al., 2010) evaluated 12 SCT carriers and 12 controls and had them exercise for 40
minutes of submaximal exercise. Both the SCT carrier group and the control group
performed the same exercise twice, once with water offered ad libitum and again without
water. Both blood viscosity and RBC rigidity were elevated in SCT carriers at baseline
relative to controls, but viscosity and RBC rigidity both decreased to the same level as the
control group when the exercise was performed while hydrated. The non-SCT control
group who did not hydrate during exercise did not experience any change in RBC rigidity
and had only a non-significant increase in blood viscosity with exercise and this
decreased to baseline in the recovery phase.
1.2.3.3. Alpha Thalassemia.
In addition to have having a lower hemoglobin S percentage as mentioned above,
people who co-inherit both a single or double loss of an α-globin gene and SCT have
fewer physiological abnormalities than do SCT carriers without any degree of α
14

thalassemia, as seen in the study on capillary tortuosity as by (L. Vincent et al., 2010) and
levels of adhesion molecules (Monchanin et al., 2008). MDA levels in the study by
Chirico et al (Chirico et al., 2012) were higher in SCT carriers without α-thalassemia
after undergoing strenuous exercise, as well as a significantly lower change in nitrogen
oxide metabolism from baseline.
1.3. Conclusion
Under certain circumstances, SCT can provoke rhabdomyolysis. The most
commonly postulated mechanism by which this happens is via changes to the red blood
cell that increase adhesion, blood viscosity, and the activity of inflammatory molecules.
This is thought to lead to vascular and endothelial changes which ultimately increase the
risk of micro-occlusions in the musculature which lead to muscle necrosis and release of
intracellular components. Mitigating this is the presence of α-thalassemia trait, physical
fitness, and adequate hydration which appear to downregulate his process.
Arguing against this mechanism is the paucity of data demonstrating actual
microvascular occlusions in SCT carriers as well as more recent vigorous
epidemiological data suggesting that the association of exertional rhabdomyolysis with
SCT is lower than was once thought (Nelson et al., 2016). An alternative explanation for
the association of SCT and exertional rhabdomyolysis is the co-inheritance of other
genetic abnormalities with SCT, such as glucose -6-phosphate dehydrogenase deficiency
or differences in intra-cellular calcium receptors (P. Connes, Harmon, & Bergeron,
2013).
15

More research is needed into the pathophysiology of rhabdomyolysis in SCT
carriers, specifically in the development of microvascular obstruction or muscle ischemia.
The recent characterization of a mouse model of SCT may be helpful with this (Zappia et
al., 2017) given the ethical problems this would pose in testing human volunteers. The
fact that the exact mechanism remains difficult to prove may be good news for SCT
carriers as it suggests that exertional rhabdomyolysis is a rare event, and supports the
American Society of Hematology’s recommendations against universal SCT testing in
athletic participation (Thompson, 2013).
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CHAPTER 2: ASSOCIATION OF SICKLE CELL TRAIT WITH ATRIAL
FIBRILLATION: THE REGARDS COHORT
2.1. Introduction
Sickle cell trait (SCT) is the heterozygous, purportedly asymptomatic carrier state
for sickle cell disease (SCD) and is present in approximately 8% of African-Americans
(Ojodu et al., 2014). SCD profoundly affects individuals’ quality of life and leads to
painful vaso-occlusive crises and progressive disability leading to early death. Once
thought to be a benign condition (Motulsky, 1973), SCT is associated with an increased
risk of chronic kidney disease (CKD) (R. P. Naik et al., 2014; R. P. Naik & Haywood,
2015), and other medical conditions (Austin et al., 2007; Davis, Mostofi, & Sesterhenn,
1995; Harmon et al., 2012; Kark et al., 1987; Tsaras, Owusu-Ansah, Boateng, &
Amoateng-Adjepong, 2009). Previous studies have shown no evidence to date that SCT
leads to a lower life expectancy (Ashcroft & Desai, 1976; Stark, Janerich, & Jereb, 1980),
or stroke (H. I. Hyacinth, Carty, Seals, & et al., 2018), and there are mixed data on the
association with coronary artery disease (Bucknor, Goo, & Coppolino, 2014; Hyacinth I
Hyacinth et al., 2016; Nelson et al., 2016). Prior studies have not examined associations
between arrhythmias such as atrial fibrillation (AF) and SCT.
AF has been documented in SCD patients in multiple studies (Bode-Thomas,
Hyacinth, Ogunkunle, & Omotoso, 2011; Garadah, Gabani, Alawi, & Abu-Taleb, 2011;
Holloman, Johnson, & Haywood, 1987; Upadhya et al., 2013). In contrast to SCD, there
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are no similar studies documenting AF in SCT carriers. Cardiac problems in people with
SCT have focused on athletes and sudden cardiac death (Key, Connes, & Derebail, 2015;
Tsaras et al., 2009). We evaluated the association with SCT and AF as AF is a common
condition with an increasing prevalence (Piccini et al., 2012) especially as the population
ages and is a risk factor for ischemic stroke and heart failure (Zoni-Berisso, Lercari,
Carazza, & Domenicucci, 2014).
Naik et al. demonstrated an association of SCT with an increased risk of CKD in
several cohorts, including the REasons for Geographic and Racial Differences in Stroke
(REGARDS) study (R. P. Naik et al., 2014; R. P. Naik & Haywood, 2015). CKD and
hypertension are known risk factors for AF (Watanabe et al., 2009), and SCT may be
associated with AF by other poorly defined mechanisms beyond simply exacerbating
other known risk factors. Thus we hypothesized that SCT would be associated with an
increased risk of prevalent and incident AF in African-Americans.
2.2. Methods
2.2.1. Study Cohort
REGARDS recruited 30,239 black and white men and women over 45 years old
from 2003-2007, with the principal aim of identifying causes of racial and regional
disparities in stroke incidence and mortality in the United States. The detailed study
design has been published (Howard et al., 2005). REGARDS recruited individuals from
a commercially available list of U.S. residents. Participants were excluded if they could
not speak English, had a self-reported race other than black or white, were on a waiting
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list for a nursing home, or had active cancer in the past year. Using a computer-assisted
telephone interview, interviewers obtained demographic information and a cardiovascular
medical history, including a physician diagnosis of AF. Consent was obtained initially on
the telephone and subsequently in writing during an in-person evaluation 3-4 weeks later.
During the visit, staff obtained blood and urine samples, medication history, and
performed a resting ECG. ECGs were centrally interpreted for factors including prevalent
AF. Participants were followed every 6 months by telephone for possible stroke and
other outcomes (Soliman et al., 2012). A second in-home visit was performed an
average of 9.2 years later among available REGARDS participants, where participants
gave their health history and a second ECG was performed, and similarly interpreted for
AF.
SCT status was determined by direct genotyping for rs334 using TaqMan®
(Hyacinth I Hyacinth et al., 2016; R. P. Naik & Derebail, 2017).
Genotyping for SCT was not performed on participants who self-reported as
white. For this analysis, REGARDS participants were excluded if they did not selfidentify as black, did not have stored DNA or consent for genetics research, or if they had
hemoglobin SS (SCD) or hemoglobin SC disease (a related sickling hemoglobinopathy).
REGARDS was approved by the institutional review boards of all participating
institutions and was conducted according to the provisions of the Declaration of Helsinki.
2.2.2. Outcomes
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For the cross-sectional analysis, as previously reported (Soliman et al., 2011), AF
was defined at baseline as ECG evidence of AF at the time of the in-home physical exam
or as a self-reported physician diagnosis of AF. For the incident AF analysis, incident
AF was defined as a self-reported physician diagnosis of AF or ECG evidence of AF in
those free of AF by ECG or self-report at baseline and was assessed in the form of a 2nd
in-home visit.
2.2.3. Definitions
Age was specified as age at the time of entry into the REGARDS cohort. Income
was categorized as <$20,000, $20,000-34,999, $35,000-74,999, or ≥$75,000 annually,
and education as less than high- school, high-school graduate, some college, and college
and above. Cardiovascular disease (CVD) was defined as a self-reported physician
diagnosis of prior myocardial infarction or stroke. Hypertension was defined as the use
of antihypertensive medications, or a resting in-home systolic blood pressure reading of
≥140 mmHg. Diabetes was defined as a prior self-reported physician diagnosis of
diabetes, or the use of oral medications or insulin, excluding gestational diabetes. CKD
was stratified into four groups (stage 0-1, 2, 3, 4+) according to the Kidney Disease:
Improving Global Outcomes 2012 Clinical Practice Guidelines (Levey et al., 2011)
incorporating estimated glomerular filtration rate from the CKD-EPI equation (Levey &
Stevens, 2010) and urine albumin concentration.
2.2.4. Statistical analysis
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Baseline characteristics were compared by SCT status using chi-square analysis
and t-tests for continuous variables. Staged logistic regression models were used to
calculate odds ratios (ORs) of AF by presence of SCT. Covariates were added in three
steps:
Model 1: adjusted for age, sex, income, and education
Model 2: Model 1 + body mass index, history of CVD, and diabetes
Model 3: Model 2 + CKD and hypertension

The purpose of Model 3 was to test for possible mediation of the association by
CKD and hypertension, given the known association of SCT with CKD (R. P. Naik et al.,
2014). In addition to model 3, to control for population substructure, 10 principal
components (PC) of genetic ancestry were generated in Eigenstrat (Tran et al., 2015) and
added to Model 3. PC of genetic ancestry were measured in a case-control study and
available in 67 percent of African-American REGARDS participants. As PCs were not
available in all individuals, we assessed the association of SCT with AF only in those
with PCs of ancestry available, excluding those without data. Additionally, a sensitivity
analysis using electrocardiogram documented AF only was performed. Unadjusted
baseline associations were also compared using Chi square analysis. All two-sided p
values < 0.05 were considered significant.
The above analyses were repeated in those who had a 2nd home visit by
REGARDS investigators who were free of AF at the initial visit to determine the OR of
incident AF based on AF status at the second examination. Given that it is not possible to
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estimate the precise timing of developing AF based on ECG evidence seen on the 2nd
home visit, cox proportional hazard models could not be used
All analysis was performed using STATA v 14.1 (StataCorp. 2015. Stata
Statistical Software: Release 14. College Station, TX: StataCorp LP.)
2.3. Results
There were 10,433 African-American REGARDS participants who had
genotyping for SCT as well as ECG and complete medical history (83% of the 12,514
African Americans in the study). Ten individuals homozygous for hemoglobin SS (sickle
cell anemia) (0.09%) and 14 (0.13%) with hemoglobin SC disease were excluded from
the analysis. There were 778 participants with SCT (7.5%). Figure 2 outlines how many
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participants were excluded or had missing data at each stage of the analysis.

Figure 2: Summary of participant exclusions and missing data

Overall, 811 (7.8%) of these participants had either a medical history and/or ECG
evidence of AF at baseline. Table 1 summarizes the baseline characteristics of
participants with and without SCT.
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Table 1: Baseline characteristics of African American REGARDS participants by Sickle Cell Trait
Status

Mean Age (SD)
Female
Income < $20,000/year
Less than high school education
Mean BMI (SD)
History of cardiovascular disease
Diabetes
Stage 4 or higher chronic kidney disease
Hypertension
Mean Systolic Blood Pressure (SD)
Atrial Fibrillation

No Sickle Cell
Trait
64 (9)
61%
38.9%
19.7%
30.8 (6.7)
13.7%
30.3%
1.4%
66%
131 (17)
7.3%

Sickle Cell
Trait
63.5 (9)
64%
40.9%
19.2%
30.7 (6.8)
13.5%
32.2%
2.9%
63%
132 (17.7)
9.5%

pvalue
0.14
0.10
0.28
0.84
0.72
0.85
0.25
0.001
0.07
0.26
0.02

The mean baseline age was 64 years (range 45-96). Twice as many participants
with SCT had stage 4 kidney disease by KDIGO criteria (2.9% vs 1.4% for people with
and without SCT respectively, p=0.001).
Table 2 outlines the main results of the cross sectional analysis. Overall, SCT was
associated with an approximately 1.3-fold increased odds of AF in all models (lower limit
of the 95% CI >1.0). In Model 1 (the demographic model) the OR (95% CI) was 1.32
(1.03-1.70). Further adjustment for AF risk factors (Model 2) or for CKD and
hypertension (Model 3) did not attenuate or strengthen the association of SCT with AF.
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Table 2 Odds Ratios (ORs) and 95% Confidence Intervals (CIs) of prevalent atrial fibrillation with
sickle cell trait

N
N with prevalent AF
OR (95% CI)
Model 1
10,409
811
1.32 (1.03, 1.70)
Model 2
10,295
797
1.33 (1.03, 1.71)
Model 3
10,241
793
1.32 (1.02, 1.70)
Model 1: adjustment for age, sex, income and education. Model 2: Model 1 +
adjustment for body mass index, cardiovascular disease history, diabetes. Model 3:
Model 2 + adjustment for chronic kidney disease and hypertension.

At the second in-home visit, an average 9.2 years after baseline, 4,836 participants
with baseline known AF status and genotyping had an ECG. There was a similar
association with incident AF and SCT as seen in prevalent AF with the OR in model 3
being 1.25 but the 95% confidence intervals were wider and crossed 1 (0.77, 2.03) (Table
3).
Table 3: Odds Ratios (ORs) and 95% Confidence Intervals (CIs) of incident AF over 9.2 years by
sickle cell trait

N

N with incident AF

OR (95% CI)

Model 1

4,836

208

1.25 (0.77, 2.03)

Model 2

4,795

206

1.27 (0.78, 2.07)

Model 3

4,764

206

1.28 (0.78, 2.08)

Model 1: adjustment for age, sex, income and education. Model 2: Model 1+
adjustment for body mass index, cardiovascular disease history, diabetes. Model 3:
Model 2 + adjustment for chronic kidney disease and hypertension.

In a sensitivity analysis classifying prevalent AF as AF present at either
REGARDS exam, the association of SCT with AF was stronger than in analysis from the
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baseline visit, with an OR of 1.39 (1.01, 1.92) for model 3 (Table 4). In this analysis, the
total prevalence of ever having reported a history of AF or ever having ECG evidence of
AF in the participants available for a 2nd in-home visit was slightly higher than the main
cohort, at 10.1%.
Table 4 Odds Ratios (ORs) and 95% Confidence Intervals (CIs) of cross-sectional analysis of all
prevalent AF at 2nd in-home visit by sickle cell trait

N
N with prevalent AF
OR (95% CI)
Model 1
4,836
490
1.43 (1.05, 1.97)
Model 2
4,795
483
1.41 (1.03, 1.94)
Model 3
4,764
482
1.39 (1.01, 1.92)
Model 1: adjustment for age, sex, income and education. Model 2:
Model 1+ adjustment for body mass index, cardiovascular disease
history, diabetes. Model 3: Model 2 + adjustment for chronic kidney
disease and hypertension

In an additional sensitivity analysis of the odds of prevalence of ECG evidence of
AF, the association of SCT with AF was greater, with ORs of 1.7-1.8 in all three models,
while the association was weaker for AF defined by history alone (OR of 1.26 in all three
models), but in both instances the 95% CIs included 1.0. When we restricted the analysis
to individuals with PCs of genetic ancestry available, there was no association of SCT
with AF in this subset (OR 1.01; 95% CI 0.71, 1.44), as such we did not further pursue
adjusting for PC of genetic ancestry in additional models.
2.4. Discussion
The main findings of this study were a 32% higher odds of prevalent AF in
African Americans with SCT after adjusting for age, gender, education, income, and
cardiovascular disease. Additional adjustment for CKD or hypertension did not attenuate
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this association. There was also a 26% higher odds of incident AF, though this finding
was not statistically significant.

To our knowledge, the association of SCT with AF has not been reported before.
We had hypothesized that SCT could be associated with AF by acting through the
intermediaries of CKD (Watanabe et al., 2009) which in turn may be associated with
hypertension (Kannel, Abbott, Savage, & McNamara, 1982). Arguing against CKD and
hypertension mediating the association of SCT with AF is that after adjusting for CKD,
hypertension, and known cardiovascular disease, the association of SCT with AF did not
meaningfully change. These data are confusing but consistent with the surprising but
robust recent epidemiological research demonstrating that SCT was not independently
associated with risk of ischemic stroke among African Americans in the United States
(H. I. Hyacinth et al., 2018), even though ischemic stroke is associated with CKD and
SCT is associated with risk of CKD.

While we have previously shown the substantial accuracy of self-reported
AF(Soliman et al., 2011), a strength of this study includes the ability to capture AF data
by both medical history and ECG. Medical history reported by REGARDS participants
has also been validated by comparing it with Medicare claims data in other
cardiovascular diseases (Colantonio et al., 2017) and it provides a better capture of
paroxysmal or persistent AF. These are conditions which are still associated with
thromboembolism and that require anticoagulation (Ganesan et al., 2016) as well as
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rhythm-controlled AF, and reported history of AF has been found to be a significant risk
factor in developing ischemic stroke (Soliman et al., 2011). Furthermore, when a more
strict definition of AF by ECG criteria alone was used, the direction of the association
was similar with a greater magnitude. Additionally, the fact that there was a similar
prevalent and incident association is helpful in that is provides an internal replication of
results.
This study has several limitations. While data on prevalent AF at the time of entry
into the study is robust, the data on incident AF was less so: medical histories and a
second in-home ECG were available from only about half of the participants, with
approximately 12% dying between visits, 21% withdrawing from the study, and 21% not
assessed for other reasons. The number of participants with incident AF was relatively
small so our power was limited. Finally, when we looked at the subset of participants
with PC of genetic ancestry available there was no association between SCT and AF. PC
data was available in only a subset of the cohort, and as there were significantly more
participants with AF in the subset that did not have PC data available, it appeared to be
non-random, rather than a simple loss of power. In theory, SCT could be a marker of
another nearby mutation and adjusting for population substructure may have attenuated
this association. While possible, this would be unlikely due to the known pathologic
implications of SCT and SCD as well as lack of attenuation of SCT with adverse
outcomes after adjusting for PC of genetic ancestry for other diseases in other
populations (H. I. Hyacinth et al., 2018; R. P. Naik et al., 2014). Finally, as genotyping
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for SCT was limited to African American participants in REGARDS, these findings may
not be generalizable to people of other races or living in other regions.

2.5. Conclusion
SCT was associated with AF independent of risk factors for AF. The mechanism
does not appear to act through CKD and hypertension, known risk factors for AF and
conclusions regarding a proposed mechanism cannot be drawn from the data. Given the
association of hypertension and CKD with AF, these data support the need to better
understand the clinical consequences of SCT as well as other polymorphisms which may
impact the association of SCT with cardiovascular diseases. These data add AF to the
potential diseases associated with SCT and demonstrate the keen need to understand the
health consequences of SCT as it seems less and less to be an asymptomatic carrier state
of a common genetic disease.
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